A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

NCT00612534 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Post Operative Pain

Interventions

DRUG: Sufentanil NanoTab
DRUG: Placebo NanoTab
DRUG: Sufentanil NanoTab
DRUG: Sufentanil NanoTab

Sponsor

Talphera, Inc